Levothyroxine Sodium

原研药和仿制药到底差在哪？ 去药店买降压药，药师一句话问倒很多人：“要进口的还是国产的？”同一种成分，价格能差20倍。贵的那个是“智商税”吗？便宜的那个，敢吃吗？ “医生，你给我开便宜的行吗？隔壁老王说贵的都是智商税。” “大夫，还是给我用进口的吧，贵点没事，吃着踏实。” 在门诊和药房，这样的对话每天都在发生。同一种成分，比如氨氯地平，进口原研药一盒几十块，国产仿制药几块钱；降糖药达格列净，集采前4.36元一片，集采后最低0.215元一片——价格差了20倍。 算一笔账：一年下来，光这一种药就从1591元降到78元，省下的钱够全家做一次全面体检。 这可能是普通人买药时最高频的纠结。今天不站任何一方，把监管标准、科学证据和真实世界数据摆出来，最后给你一套能直接用的选择逻辑。读完你会发现，选择的关键，根本不在于“贵还是便宜”。 点击下方名片 关注我们 PART/1 原研药和仿制药到底差在哪？ 一、先搞清楚：它俩到底是什么关系 原研药（俗称“进口药”“品牌药”），是第一个把这个分子研发出来的药。一款新药从实验室到上市，平均耗时约10年、投入数十亿美元，要经过动物实验和三期人体临床试验，在数千名患者身上证明疗效和安全性。 作为回报，它获得约20年专利保护期——这期间只有它能卖，价格自然高，本质是在回收研发成本。经典例子是电影《我不是药神》里的格列卫：专利期内每盒2万多元，专利到期后仿制药降至千元级。 仿制药，是专利到期后，其他厂家照着公开的“答案”生产的同一种药。活性成分、剂型、规格、给药途径必须和原研药完全一致。但仿制药企业不需要重复几十年的研发和大规模临床试验，只需要做一件核心的事：证明自己和原研药“生物等效”。 打个比方：原研药是第一个写出菜谱、反复试菜定下口味的餐厅；仿制药是照着同一份菜谱做菜的其他餐厅。主料必须一样，但灶台、手艺、调料细节可以有差别——监管要做的，就是尝一口，确认端上桌的菜味道没区别。 因为省掉了研发成本，仿制药价格通常只有原研药的10%~30%。这就是价差的来源：差的主要是研发成本和品牌溢价，不是你手里那片药的成分。 💡 一句话：原研药是“原创发明”，仿制药是“过了严格考试的复刻版”——都不是假药。 ⚠️ 避坑提醒： 药盒上若印有“原研一致”字样，别当成官方认证——这曾是某企业注册的商标名，与质量认证无关，已被市场监管部门立案调查。真正的官方标识是“仿制药质量和疗效一致性评价”标识，药盒上有专属图案。 PART/2 原研药和仿制药到底差在哪？ 二、“生物等效”是怎么测的？80%~125%不是你想的那个意思 仿制药上市前的核心考试叫生物等效性试验（BE试验）：找一批健康志愿者，交叉服用原研药和仿制药，定时抽血，比较两个关键指标—— AUC（药物进入血液的总量，反映“吸收了多少”） Cmax（血药浓度峰值，反映“吸收得快不快”） 国际通行标准（美国FDA、欧洲EMA、中国NMPA一致）是：仿制药与原研药的AUC和Cmax比值，其90%置信区间必须落在80%~125%之间。 这个“80/125规则”是被误解最多的数字。很多人以为“国家允许仿制药比原研药差20%”，完全不是： 第一，这是统计学置信区间，不是实际差值。 它要求的是“整个误差范围都落在窗口内”，逼着仿制药的实际均值必须非常贴近100%。FDA对2000多项BE研究的分析显示，获批仿制药的实际吸收差异平均不到4%，98%的产品落在90%~110%这个更窄的范围里。理论上的80%和125%极端值，现实中几乎碰不到。 第二，差的不是成分含量，是身体的吸收过程。 药片里活性成分的毫克数必须一模一样，BE测的是吃下去之后，身体吸收的速度和程度。 第三，这个考试原研药自己也要过。 原研药上市后如果换生产场地、改工艺、调辅料，同样要做BE试验证明“没变”。从这个角度说，货架上的原研药，其实也在不断被“证明和当年临床试验那批药等效”。 那为什么总有人说“换了仿制药感觉效果差了”？这里有几个真实存在的缝隙，后面专门讲；但也要承认一个统计事实：个人感受是最不可靠的证据。 国家医保局在回应质疑时举过二甲双胍的例子——全国一年使用集采二甲双胍100多亿片，规范研究显示糖化血红蛋白达标率原研组78.9%、仿制组83.4%，空腹血糖达标率87.6% vs 83.8%，互有高下、无统计学差异。两边都有约20%的患者疗效不佳。从100多亿片里挑几个“换药后没效”的例子，和挑几个“原研药没效”的例子一样容易。个例有冲击力，但证明不了因果。 PART/3 原研药和仿制药到底差在哪？ 三、中国的答卷：一致性评价+集采，30万患者的真实世界数据 中国仿制药曾经确实有过“水货”年代——2016年以前，大量仿制药是按老标准批准的，没有和原研药做过严格对比。这也是很多人“国产药不行”印象的根源。 但过去十年，这套体系被推倒重建了，关键动作是两个： 1. 仿制药一致性评价。 2016年起，国家要求所有仿制药必须证明自己与原研药质量和疗效一致，考不过的注销批文。截至2026年3月，国家药监局已发布103批参比制剂目录（涉及2879个品种），通过或视同通过一致性评价的药品达1695个，约占临床常用化学药品的2/3；审评标准已全面采纳ICH国际技术指导原则，和国际标准全面接轨。药品抽检总体合格率持续保持在99%以上。 2. 国家集中带量采购（集采）。 以“通过一致性评价”为入场券，国家以超级大买家的身份议价。截至目前已开展11批，覆盖490个品种。第十一批集采平均降幅超50%，达格列净片从4.36元/片降到0.28元/片，糖尿病患者一年药费省超1400元。便宜下来的前提是：所有中选药都过了一致性评价，且药监部门对中选企业GMP检查、中选品种抽检“两个全覆盖”——已有18个集采药品因质量问题被取消中选资格，相关企业最长4年禁入。 📊 30万人的答案 近百家三甲医院 · 前7批集采药品 · 纳入患者超30万结论：中选仿制药与原研药总体等效，无显著统计学差异。 医保部门组织全国近百家三甲医院，对前7批集采中选药品开展真实世界评价，纳入患者样本量超过30万人。几个具体的： 降压药氨氯地平：瑞金医院、西安交大一附院、中山七院等多家中心分别研究，原研与仿制在降压效果、用药依从性、不良反应发生率上均无差异 降糖药二甲双胍：宣武医院数千例患者对比，血糖达标率两组相当 抗肿瘤药卡培他滨：29家医院14万病例的研究里，仿制组治疗缓解率50%，甚至高于原研组的30% 作为参照，美国仿制药处方占比约90%，日本约80%——用仿制药是全球主流做法，不是“降级消费”。 PART/4 原研药和仿制药到底差在哪？ 四、但这几种情况，请谨慎对待仿制药 说到这里，不等于“所有药闭眼选仿制”。科学上确实有几类药物，生物等效的“统计窗口”可能在个体身上被放大，切换时要格外小心： 1. 窄治疗指数药物（NTI）。 这类药“有效剂量”和“中毒剂量”离得特别近，血药浓度轻微波动就可能导致要么失效、要么中毒。代表：华法林（抗凝）、地高辛（强心）、锂盐（精神科）、环孢素（免疫抑制）、左甲状腺素（补甲状腺激素）。对这类药，各国监管的BE窗口本身就收得更窄，临床上也建议尽量固定使用同一个厂家的产品，不要频繁换品牌。 2. 抗癫痫药。 血药浓度短暂波动就可能诱发突破性发作。美国癫痫学会的立场声明建议：癫痫患者维持治疗期间应避免在不同品牌间频繁切换；而且研究提示，在两个不同厂家的仿制药之间反复换，风险甚至比原研换仿制更高。 3. 复杂剂型。 透皮贴剂、缓释/控释制剂、脂质体、吸入剂等，仿制工艺难度高，释放行为的差异更难完全复制，切换时留意效果变化。 4. 生物制品（胰岛素、单抗等）。 它们不是化学小分子，结构极其复杂，严格说没有“仿制药”，只有“生物类似药”。生物类似药同样经过严格审评，但换药决策应由医生评估，不建议自行替换。 5. 辅料过敏或不耐受。 药片里活性成分之外的辅料（填充剂、黏合剂、包衣等）平均占药片重量的约70%，不同厂家可以不同。辅料不是“惰性”的——极少数人会对特定辅料过敏，或因乳糖、甘露醇等差异出现胃肠不适。换药后若出现皮疹、莫名胃肠反应，值得往这个方向查。 PART/5 原研药和仿制药到底差在哪？ 五、给普通人的选择清单 把上面的证据浓缩成可执行的建议： ✅ 放心选仿制（优先过评/集采药）的情况： 高血压、糖尿病、高血脂、胃病等慢病常用口服药（氨氯地平、二甲双胍、阿托伐他汀、奥美拉唑等） 普通抗生素、抗过敏药、消炎止痛药等短期用药 认准包装上的 “通过仿制药一致性评价”标识，或医院/药店提供的集采中选品种 这些药有BE试验背书、有99%以上抽检合格率、有30万人真实世界数据兜底。疗效差异远小于“按时吃药vs三天打鱼两天晒网”带来的差异。 ⚠️ 建议与医生商量、尽量固定品牌的情况： 正在吃华法林、地高辛、锂剂、左甲状腺素、环孢素等窄治疗窗药物 癫痫、心律失常等对血药浓度敏感的疾病 使用胰岛素、单抗类生物制剂 既往换药后明确出现过疗效下降或不良反应 🔄 换药后的正确姿势： 不要自己频繁在不同厂家之间横跳 换药后2~4周内监测关键指标，用数据说话，而不是凭“感觉” 出现明确不适，找医生或药师评估，不要直接断定“药不行”——也可能是辅料、合并用药或病情变化 📋 换药后自查卡（建议截图保存） 总结 同一种药，药店报价差10倍： 原研药和仿制药到底差在哪？ 最后纠正两个流行偏见 “便宜没好货”——在药品领域，这个逻辑不成立。 价格主要由研发成本和竞争格局决定，和单片质量的相关性早已被一致性评价体系切断。集采中选药是“质量门槛上的价格战”，不是“降低质量的降价”。 “原研药就是智商税”——也不对。 原研药承担了从零到一的创新风险，今天你吃到的每一种仿制药，前提都是原研药当年把路走通了；对治疗窗极窄的危重患者，多花的钱买的是确定性，值得。 没有最好的药，只有最适合你病情和钱包的药。 绝大多数人、绝大多数常见病，过评仿制药是医疗普惠的礼物，该用就用；少数特殊药物、特殊人群，原研药的确定性依然重要。选择权在你手里，但判断应该基于证据，而不是药店货架的高度和价格标签的位数。 📌 说明： 本文为健康科普，不构成个体化用药建议。具体用药选择请遵医嘱或咨询药师。 觉得有用？转发给家里管买药的那个TA👇 “公众对药品的信任，不是靠广告建立的，而是靠每一个通过检验的批次积累的。” ——美国FDA前局长 玛格丽特·汉堡（Margaret Hamburg） 微信公众号丨医语心 说明 模板：秀米 插图：剪映 编辑：怡然

Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive clinical development strategy, including Cornerstone, its Phase 3 registrational study design, as well as the commercial opportunity for XP-8121, its investigational once-weekly subcutaneous levothyroxine formulation for the treatment of hypothyroidism. "We are excited to showcase our comprehensive development program for XP-8121 and highlight why we have a high level of confidence in its success,” said John Shannon, Chairman and Chief Executive Officer, Xeris. “With a well-established unmet need, and a differentiated product profile, we believe that XP-8121 could reach $1 to $3 billion in peak net revenue, cementing Xeris as a leading biopharmaceutical company. And most importantly, if approved, XP-8121 has the potential to redefine care and improve the lives of millions of patients." XP-8121's Comprehensive Evidence Generation Program Cornerstone — Phase 3 Registrational Study Objective : To demonstrate that once-weekly subcutaneous XP-8121 is therapeutically equivalent to daily oral levothyroxine in patients with well-controlled hypothyroidism, as required by the U. S. Food and Drug Administration (FDA) for approval. Design : Randomized 1:1 controlled study; participants receive subcutaneous XP-8121 or oral levothyroxine for 54 weeks, with treatment assessments and laboratory evaluations conducted every six weeks throughout the study. Enrollment : 500 adults and adolescents with well-controlled hypothyroidism across more than 50 U. S. clinical trial sites, representing both community and academic settings. Primary endpoint : Proportion of subjects with thyroid-stimulating hormone (TSH) within the normal range at both weeks 48 and 54. Key secondary endpoints : Proportion of time TSH and Free T4 are each within normal range during the final 30 weeks of the study; supportive pharmacokinetic (PK) and PK/pharmacodynamic (PD) endpoints designed to quantify the clinical advantages of once-weekly subcutaneous delivery. Statistical design : 15% non-inferiority margin; greater than 90% power; informed by feedback from the FDA on endpoints and statistical powering. Capstone — Pediatric Study Objective : To confirm appropriate dosing and evaluate safety of XP-8121 in pediatric patients, extending the evidence base across all age groups. Touchstone — Special Population Study Objective : To evaluate XP-8121 in patients with inconsistent thyroid control despite maximal oral therapy. Real-world evidence Objective : To quantify the burden and consequences of inadequate thyroid control through ongoing analyses of claims and real-world datasets conducted in collaboration with leading experts in the field. Clinical Perspective In addition to Company representatives, key opinion leader and Cornerstone investigator Dr. David Robertson, a leading endocrinologist at Atlanta Diabetes Associates and Piedmont Hospital Atlanta with nearly three decades of experience treating complex thyroid and metabolic conditions, will participate in today's program overview. “As an endocrinologist and clinical investigator, I see firsthand the challenges that persist for patients who cannot achieve TSH normalization on existing oral therapies,” said Dr. David Robertson. “Despite our best efforts, a meaningful subset of patients faces a frustrating cycle of dose escalations, repeated testing, and persistent symptoms, driven by factors such as unreliable GI absorption, drug interactions, and comorbid conditions. For the first time in decades, XP-8121 offers a fundamentally different approach to levothyroxine delivery. It has the potential to help difficult-to-treat patients achieve biochemical control and reach their treatment goals. The Phase 1 and Phase 2 data provide meaningful foundation around its safety pro dose-conversion results, and I look forward to serving as an investigator in the Cornerstone study to help in the process towards generating additional data and potentially bringing a new option closer to the patients who need it most.” How to Register and Access the Event The XP-8121 Program Overview webinar will be held today, Wednesday, September 9, at 10 a.m. ET . For registration and access, please click here . A replay of the event, along with the related presentation materials, will also be made available on the "Events and Presentations" section of the Company's Investor Relations website following the live presentation. About Hypothyroidism Hypothyroidism affects approximately 20 million Americans, the majority of whom are managed with daily oral levothyroxine. Despite treatment, an estimated 3 to 5 million patients fail to achieve adequate biochemical control, largely due to gastrointestinal absorption variability associated with oral administration. Uncontrolled hypothyroidism is associated with meaningful clinical consequences, including cardiovascular disease and increased mortality. About XP-8121 XP-8121 is a Phase 3-ready, once-weekly subcutaneous injection in development for the treatment of hypothyroidism. The program is designed to address persistent challenges associated with existing thyroid hormone replacement therapy and has the potential to provide a differentiated treatment option for people living with hypothyroidism and physicians. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev ® , for the treatment of endogenous Cushing’s syndrome; Gvoke ® , a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis ® , a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol ® and XeriJect ® , for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for the Company, including among other things, statement regarding the Company’s comprehensive clinical development program for XP-8121, the design, objectives, endpoints, enrollment, timing, conduct and expected results of the Cornerstone, Capstone, and Touchstone studies, the ability of XP-8121 to demonstrate therapeutic equivalence of daily oral levothyroxine, achieve applicable clinical endpoints and support regulatory approval, the expected initiation of Cornerstone by year-end 2026, the expected initiation of Touchstone in 2027 and completion of Touchstone in time for inclusion in the Company’s New Drug Application submission, and the expected timing of topline results in late 2028, the timing and likelihood of regulatory approval and commercialization of XP-8121, including potential FDA approval and commercial launch in 2030, the market and therapeutic and commercial potential of its products and product candidates, including its expectations regarding the potential of XP-8121 to provide biochemical control, improve patient outcomes and redefine care, and its estimated peak net revenue or sales potential of $1 billion to $3 billion, the timing, duration, and expected results of clinical trials, the timing and expected regulatory approval of its product candidates, the potential utility of its formulation platforms, the advancement of its pipeline, and other statements containing the words "achieve," "anticipate," “believe,” “continue,” “expect,” “estimate,” “potential,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors, and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results (including revenue and sales in the near- and long-term), performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements , include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the risk that clinical trials may not be initiated, enrolled, or completed on anticipated timelines, or at all, the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials or may not support regulatory approval, the possibility that the FDA may disagree with the design or conduct of the Company’s clinical trials or require additional clinical trials or data, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, political unrest, trade disputes, changes in U.S. governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ U.S. Securities and Exchange Commission filings are not the only risks the Company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. Contacts Investor Contact Allison Wey Senior Vice President, Investor Relations ir@xerispharma.com